| pubmed-article:18503261 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18503261 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18503261 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:18503261 | lifeskim:mentions | umls-concept:C0085295 | lld:lifeskim |
| pubmed-article:18503261 | lifeskim:mentions | umls-concept:C1705413 | lld:lifeskim |
| pubmed-article:18503261 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:18503261 | lifeskim:mentions | umls-concept:C0547047 | lld:lifeskim |
| pubmed-article:18503261 | lifeskim:mentions | umls-concept:C0205420 | lld:lifeskim |
| pubmed-article:18503261 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:18503261 | pubmed:dateCreated | 2008-5-27 | lld:pubmed |
| pubmed-article:18503261 | pubmed:abstractText | The cytotoxic T lymphocyte antigen-4 (CTLA-4) molecule on T cells acts to maintain homeostasis by regulating the proliferation of recently activated T cells. Blockade of CTLA-4 by anti-CTLA-4 antibody enhances T cell responses and has elicited significant tumor regression in some cancer patients. Clinical trials are ongoing to investigate the efficacy of anti-CTLA-4 antibody as a cancer therapeutic. Reports from several clinical trials have documented the occurrence of adverse events in patients treated with anti-CTLA-4 antibody which have some similarities with autoimmune conditions and have been termed immune-related adverse events (irAEs). Most irAEs are reversible with corticosteroid therapy. Some investigators suggest that irAEs occur in the same patients who have anti-tumor responses as a result of the anti-CTLA-4 antibody. Immunologic mechanisms to explain why irAEs occur in some patients have not been reported. Here we report that bladder cancer patients treated with anti-CTLA-4 antibody have increased levels of the Th1 cytokine IFN-gamma detected in plasma samples. Although IFN-gamma is a potent anti-tumor and inflammatory cytokine, increased levels of IFN-gamma were not associated with irAEs in our patients. However, in one patient who experienced an irAE consisting of ischemic papillopathy and optic neuritis, we documented high pre-therapy levels of the Th2 cytokine IL-10 which decreased after treatment with anti-CTLA-4 antibody. The decrease in plasma IL-10 concentration coincided with the patient's irAE. We propose that decreased levels of IL-10 after treatment with anti-CTLA-4 therapy may be responsible for irAEs in some patients and needs to be further investigated in larger studies. | lld:pubmed |
| pubmed-article:18503261 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18503261 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18503261 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18503261 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18503261 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18503261 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18503261 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18503261 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18503261 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18503261 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18503261 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18503261 | pubmed:issn | 1424-9634 | lld:pubmed |
| pubmed-article:18503261 | pubmed:author | pubmed-author:ChenHongH | lld:pubmed |
| pubmed-article:18503261 | pubmed:author | pubmed-author:SunJingjingJ | lld:pubmed |
| pubmed-article:18503261 | pubmed:author | pubmed-author:SharmaPadmane... | lld:pubmed |
| pubmed-article:18503261 | pubmed:author | pubmed-author:RaghunathAnit... | lld:pubmed |
| pubmed-article:18503261 | pubmed:author | pubmed-author:Ng TangDerekD | lld:pubmed |
| pubmed-article:18503261 | pubmed:author | pubmed-author:SchiffmanJade... | lld:pubmed |
| pubmed-article:18503261 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18503261 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:18503261 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18503261 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18503261 | pubmed:pagination | 9 | lld:pubmed |
| pubmed-article:18503261 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:18503261 | pubmed:meshHeading | pubmed-meshheading:18503261... | lld:pubmed |
| pubmed-article:18503261 | pubmed:meshHeading | pubmed-meshheading:18503261... | lld:pubmed |
| pubmed-article:18503261 | pubmed:meshHeading | pubmed-meshheading:18503261... | lld:pubmed |
| pubmed-article:18503261 | pubmed:meshHeading | pubmed-meshheading:18503261... | lld:pubmed |
| pubmed-article:18503261 | pubmed:meshHeading | pubmed-meshheading:18503261... | lld:pubmed |
| pubmed-article:18503261 | pubmed:meshHeading | pubmed-meshheading:18503261... | lld:pubmed |
| pubmed-article:18503261 | pubmed:meshHeading | pubmed-meshheading:18503261... | lld:pubmed |
| pubmed-article:18503261 | pubmed:meshHeading | pubmed-meshheading:18503261... | lld:pubmed |
| pubmed-article:18503261 | pubmed:meshHeading | pubmed-meshheading:18503261... | lld:pubmed |
| pubmed-article:18503261 | pubmed:meshHeading | pubmed-meshheading:18503261... | lld:pubmed |
| pubmed-article:18503261 | pubmed:meshHeading | pubmed-meshheading:18503261... | lld:pubmed |
| pubmed-article:18503261 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18503261 | pubmed:articleTitle | Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. | lld:pubmed |
| pubmed-article:18503261 | pubmed:affiliation | Department of Genitourinary Medical Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA. | lld:pubmed |
| pubmed-article:18503261 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18503261 | pubmed:publicationType | Case Reports | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18503261 | lld:pubmed |
